The Rapid Growth of Remote Patient Monitoring Solutions Can Accelerate Decentralized Clinical Trials

PharmExec.com

The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.

An influx in technologies is making it easier for pharma companies to conduct decentralized trials for all therapeutic areas, but designers of these trials need confidence in the technology’s effectiveness.

That’s why, as a RPM manufacturer, AliveCor prioritizes proving the effectiveness. For example, AliveCor received FDA clearance in 2021 for healthcare professionals to use the KardiaMobile 6L to collect a crucial piece of information about patients’ heart health: their QTc interval.

For many trials, proven RPM technology showcases that the opportunity to decentralize has arrived.

Key Takeaways:

  • The more companies embrace RMP tools, the faster we’ll normalize decentralized trials
  • Decentralized trials benefit the patient and sponsor
  • The RPM industry is growing rapidly
  • Demonstrating results and undergoing pilot programs is important to RPM manufacturers like AliveCor

Read Full Article

The Broad Impact of QT Monitoring: Extending Beyond Cardiac Health into Diverse Conditions

Beyond its traditional focus on cardiac-specific therapies, every investigational drug can potentially impact cardiac function. What if we expanded QT monitoring across various therapeutic areas?

KardiaMobile® 6L Versus 12-lead ECG: Effects on Clinic Utilization Time

Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12L ECG systems. This study published in Wiley highlights how the 6L minimizes the need for frequent conventional 12L use.

Remote Monitoring and Data Collection for Decentralized Clinical Trials

JAMAnetwork.com | Patient-centric trials require accessible digital health technologies. A JAMA study explores the current state and aspired role of remote monitoring and data collection tools in oncology trials.